Copley Scientific launches world’s first commercial apparatus for dissolution testing of inhaled drugs

25 January 2010; Nottingham, UK: Copley Scientific has launched the world’s first commercially available apparatus designed specifically for dissolution testing of inhaled drug formulations. Based on a concept developed by Professor Jason McConville and his team at the College of Pharmacy, University of Texas, a new NGI dissolution cup and membrane holder enables dissolution testing of size-fractionated particles selected from the emitted dose. Simple to use and employing analytical methodology based on established pharmacopoeial techniques for transdermal patches, it provides information that allows developers to more closely tailor inhaled drug delivery. The launch underlines Copley Scientific’s commitment to commercialising new analytical techniques for inhaled product testing and to providing the very best tools for development and QC.

Dissolution testing is widely applied in the development and manufacture of oral dosage forms, but is not yet in widespread use for inhaled products, where the prime focus is successful deposition in the lung. Currently there are no official dissolution test methods for inhaled products. However, increasing use of the pulmonary route to deliver larger molecules and/or systemic therapies means growing emphasis on the rate of active pharmaceutical ingredient dissolution. Dissolution information allows the development of more sophisticated inhalation products with delayed release characteristics and/or more closely controlled drug delivery profiles.

In dissolution testing for inhaled drugs the respirable portion of the emitted dose is of primary interest. The new solution from Copley Scientific addresses this by integrating conventional tablet dissolution testing equipment within the Next Generation Impactor (NGI), a system used routinely for aerodynamic particle size measurement to size fractionate a sample. The NGI dissolution cup fits into a conventional NGI cup tray but has a 50 mm removable insert in the impaction area, allowing the collection of particles lying in a specific size fraction. The collected sample is tested in a dissolution tester using a procedure very similar to the ‘Paddle over Disc’ technique described in the pharmacopoeia for transdermal patches. Copley Scientific also offers a similar solution for use with the Andersen Cascade Impactor.

CAPTION: Membrane holder in dissolution vessel

About Copley Scientific

Copley Scientific is recognised as the world’s leading manufacturer of inhaler test equipment and is a major supplier of test equipment for pharmaceutical solid dosage forms, including tablet dissolution, disintegration, friability, hardness and powder testers. The company has offices in the UK and Switzerland and a partnership with aerosol particle science experts MSP Corporation in North America. Copley’s broad range of testing products for metered-dose inhalers, dry powder inhalers, nebulizers and nasal sprays are supplied and supported worldwide through close relationships with specialist distributors. Serving the pharmaceutical and associated industries, Copley offers an extensive range of equipment for research, development and quality control, as well as full validation and aftersales service, providing a single source for products that meet individual needs.